2024年南半球流感疫苗预防流感相关住院的临时效果估计——REVELAC-i网络,五个南美国家,2024年3月至7月
研究利用多国网络数据,采用检测阴性病例对照设计,估计2024年3月13日至7月19日阿根廷、巴西、智利、巴拉圭和乌拉圭5国流感疫苗对流感相关严重急性呼吸道感染住院的临时效果。共识别11,751例流感相关SARI病例,平均21.3%的患者接种过流感疫苗,调整后疫苗对住院的保护效果为34.5%。
要点
- 调整后流感疫苗对流感相关住院的VE为34.5%。
- 对主要流行亚型A(H3N2)的调整后VE为36.5%。
- 对A(H1N1)pdm09的调整后VE为37.1%。
核心结论
- 这些临时VE估计提示,尽管住院患者中接种疫苗的比例不高,但接种南半球流感疫苗显著降低了住院风险。
- 因此,北半球国家应预期需要强有力的流感疫苗接种活动和早期抗病毒治疗,以实现对流感相关并发症的最佳保护。
研究设计与样本
- 研究使用多国网络数据,采用检测阴性病例对照设计估计流感疫苗对流感相关严重急性呼吸道感染住院的临时效果。
- 2024年3月13日至7月19日期间,阿根廷、巴西、智利、巴拉圭和乌拉圭共识别11,751例流感相关SARI病例。
主要发现
- 平均21.3%的患者接种过流感疫苗。
- 调整后流感疫苗对住院的VE为34.5%。
- 对主要流行亚型A(H3N2)的调整后VE为36.5%。
- 对A(H1N1)pdm09的调整后VE为37.1%。
关键数值与推荐
- 调整后流感疫苗对流感相关住院的VE为34.5%。
- 对A(H3N2)的调整后VE为36.5%。
- 对A(H1N1)pdm09的调整后VE为37.1%。
临床怎么用
- 原文指出北半球国家应预期需要强有力的流感疫苗接种活动和早期抗病毒治疗,以实现对流感相关并发症的最佳保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.
引用
- Zeno EE, Nogareda F, Regan A, et al. Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 39361525. doi:10.15585/mmwr.mm7339a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。